RECOMMENDATIONS
“Dan was an outstanding manager of the Skin Biology and Drug Delivery Laboratory at Dow Pharmaceutical Sciences. As a service provider and a profit and loss unit, Dan's unit produced the highest returns on sales, outstanding customer satisfaction and loyalty, very high morale and commitment from his staff, and the best overall financial performance in the Company over the seven year period that I was associated with Dan. He had a very insightful concept of and command of the intersection of dermatological medical practice, topical product science and technology, regulatory processes, product performance and positioning in the marketplace, the technology and science of the performance of drugs in the skin, and the probability of success of product programs in the development process and in the marketplace. He worked collaboratively and effectively with his colleagues to efficiently manage and develop his staff and others Company resources. His contributions were a key element in the unprecedented success in the development and approval of topical products enjoyed by the Company over that time.” December 12, 2010
Bill Anderson, Managing Director (2009-2010), VP Finance and Administration, CFO (2003-2009), Dow Pharmaceutical Sciences, Inc. Managed Daniel at Dow Pharmaceutical Sciences
“Dr. Bucks was a financially efficient manager that was an extraordinary teacher. He was able to bring his knowledge to basics and teach anyone at any level. His ability to teach and bring excitement to the subject made work an exciting place to be. This was an extremely powerful tool with clients as well. The knowledge I learned while working with Dr. Bucks, will carry with me throughout my career.” November 8, 2010
Bobbie Marshall, Biologist III/Project Leader, Dow Pharmaceutical Sciences reported to Daniel at Dow Pharmaceutical Sciences
“Dan has strong knowledge and skill in topical delivery of drugs and OTC active ingredients. He is a very effective interpreter of the data he generates. He understands dermatologic science.” November 11, 2010
John Quigley, Senior Vice President, Penederm, Inc managed Daniel indirectly at Penederm, Inc
“Dan is an internationally recognized expert on skin biology and is unsurpassed in his ability to complete and interpret in-vitro skin permeation testing. Dan has remained focused on this area of research for over 30 years and has played an important role in the development of the majority of topical products commercialized in the last 15 years. He has also implemented in-vitro methods for following drug transport across the cornea and sclera. Dr Bucks’ training and experience combined with excellent problem solving abilities results in Dan being able to quickly trouble shoot problems encountered throughout the development of dermatological products. He is a highly valuable asset to any team developing a product that contacts the skin.” November 5, 2010
David Osborne, VP, Product Development, Dow Pharmaceutical Sciences Inc. managed Daniel at Dow Pharmaceutical Sciences
“Dan is one of the top internationally recognized skin biologists. Dan has strong knowledge and skill in the areas of topical and ophthalmic drug delivery. He has an excellent ability in designing, interpreting in-vitro skin permeation testing, and finally selecting lead composition(s). I have learned a lot while I was collaborating with him in developing topical and ophthalmic drug products. I strongly recommend his services.” November 27, 2010
Pinaki Majhi, Scientist, Dow Pharmaceutical Sciences worked with Daniel at Dow Pharmaceutical Sciences
“Dan has over 30 years experience in academic and industrial R&D settings. He has extensive knowledge of in vitro and in vivo skin permeation and topical/transdermal product development from early stage to commercialization. Dan has been responsible for leading and creating R&D labs in industrial and academic environments and has done so in a fiscally responsible and efficient manner. Dan will add significant technical value, vast experience, highly tuned problem solving skills and pragmatism to any dermatological development program.” February 4, 2011
Gareth Winckle, R&D Formulation Team Leader, Dow Pharmaceutical Sciences worked with Daniel at Dow Pharmaceutical Sciences